Inhibitor Therapeutics reports clinical, regulatory, formulation and legal progress on September 09, 2026 annual Basal Cell Nevus Syndrome BCCNS Chancery Delaware Drug Formulation Process INTI itraconazole ITZ101 Meeting Phase IIb provisional patent Type C meeting United States Food and Drug Administration +
Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path on August 11, 2026 6-minute walk distance levosimendan Multiple Acyl Coenzyme A Dehydrogenase Deficiency PH-HFpEF primary endpoint Tenax Therapeutics Type C meeting U.S. unapproved United States Food and Drug Administration +